Valeant planning hostile takeover bid as Botox maker Allergan rejects acquisition proposals
NEW YORK, N.Y. - Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals.
Valeant Pharmaceuticals International Inc. Chairman and CEO J. Michael Pearson said in a conference call Tuesday that proxies seeking support for its bid may be mailed in "the near-term."
He said that "It is clear Allergan's management and their board will never sit down and act in the interest of their shareholders." Pearson says the Canadian company believes an Allergan shareholder vote would "be overwhelmingly in support of the deal."
The latest bid from Valeant and Bill Ackman's Pershing Square Capital Management is worth $53 billion.
California-based Allergan Inc. has repeatedly rejected offers as underpriced and risky.
Read more Business News
- Parachutist hits houseVernon / N. Okanagan - 6:47 pm
- Boonstock liquor decision finalPenticton / S. Okanagan - 7:00 pm
- Disaster relief from stormKamloops - 6:34 pm
- Movie set burned in firePenticton / S. Okanagan - 6:30 pm
|QHR Technologies Inc||1.15||0.00|
|Anavex Life Sciences||0.265||-0.01|
|Copper Mountain Mining||2.97||+0.15|
|Sunrise Resources Ltd||0.02||-0.03|
|Mission Ready Services||0.19||+0.01|
Photo: Thinkstock.comWays to reduce your Debt:Make a budget and get budget counselingA basic first step for debt reduction is to prepare a budget and plan your spending. Once you have a budget, you mu...
The Big Picture Geopolitical tensions rattle markets The spectre of rising geopolitical tensions in Ukraine and Gaza cast a shadow over an otherwise positive week in the markets. News that a passenger...
The mainstream media are finally waking up to something unusual in British Columbia – a labour shortage. If the experience of Alberta is a guide to our own future, the highly skilled labour will...